![]() You are encouraged to report negative side effects of prescription drugs to the FDA. Other adverse reactions (≥2% and >Placebo) include: anticholinergic effects, balance disorders/falls, headache, akathisia, vomiting, nausea, and arthralgia. The most common adverse reaction (≥5% and twice the rate of placebo) is somnolence. Reduce the dose or discontinue INGREZZA treatment in patients who develop clinically significant parkinson-like signs or symptoms. Parkinsonism has also been observed with other VMAT2 inhibitors. INGREZZA may cause parkinsonism in patients with tardive dyskinesia. For patients at increased risk of a prolonged QT interval, assess the QT interval before increasing the dosage. INGREZZA should be avoided in patients with congenital long QT syndrome or with arrhythmias associated with a prolonged QT interval. INGREZZA may prolong the QT interval, although the degree of QT prolongation is not clinically significant at concentrations expected with recommended dosing. Patients should not perform activities requiring mental alertness such as operating a motor vehicle or operating hazardous machinery until they know how they will be affected by INGREZZA. Based on the questions answered above, you are not eligible to register for a new copay card or to activate a copay card. Rash, urticaria, and reactions consistent with angioedema (e.g., swelling of the face, lips, and mouth) have been reported. You are eligible for a copay card Well need to collect some additional information, including a valid email address to send your card once youre registered. INGREZZA is contraindicated in patients with a history of hypersensitivity to valbenazine or any components of INGREZZA. IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS ![]() INGREZZA ® (valbenazine) capsules is indicated for the treatment of adults with tardive dyskinesia.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |